EA4232: Peripheral T Cell Lymphoma - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to compare the results of typical chemotherapy on its own to high dose chemotherapy followed by stem cell infusion after completing the usual chemotherapy. We want to know which option has the best outcomes for people with periperhal T-cell lymphoma.

¿Cuál es la Condición que se está estudiando?

Peripheral T-Cell Lymphoma

¿Quién puede participar en el Estudio?

Adultos de 18 a 75 años que:

Are diagnosed with peripheral T-cell lymphoma in one of the following categories: anaplastic large cell lymphoma (ALCL) ALK-negative, or angioimmunoblastic T-cell lymphoma (AITL), or nodal peripheral T-cell lymphoma with TFH phenotype, or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
Have previously been treated with an anthracycline based chemotherapy
Are eligible to receive high dose chemotherapy and autologous stem cell transplant

For more information, contact the study team at nick.jeffries@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

If you choose to join this study, you will get a random assignment (by chance) to 1 of 2 groups:

Group 1: If you are in this group, you will be observed once a year without any additional treatments unless your disease recurs. If that were to occur, you would be treated under your cancer doctor's guidance, which may also include the possibility of receiving a stem cell transplant as an option if you are eligible for it.
Group 2: If you are in this group, you will undergo stem cell collection, then you will receive high dose chemotherapy followed by getting your own stem cells as an infusion. You will receive the necessary supportive care measures after that until your transplanted stem cells recover. You will then be observed without any additional treatments unless your disease recurs.

Detalles del Estudio

Título Completo

EA4232: A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

Investigador Principal